Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$6.71
-0.10 (-1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $-305.3M · quality 24.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
4/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-69.6%
↓Gross Margin
29.3%
↓Debt/Equity
2.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.9%
FCF CAGR
—
FCF margin
5.9%
FCF / Net income
-0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $900.8M · net income $-287.4M · FCF $53.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $900.8M | $900.8M | $1.41B | $1.80B | $1.52B |
| Net Income | $-287.4M | $-287.4M | $-274.5M | $10.9M | $85.7M |
| EBITDA | $-127.9M | $-127.9M | $-159.6M | $104.1M | $166.3M |
| EPS | -0.72 | -0.72 | -0.69 | 0.03 | 0.21 |
| Gross Margin | 29.3% | 29.3% | 47.9% | 50.7% | 57.9% |
| Operating Margin | -17.7% | -17.7% | -16.6% | 4.2% | 8.0% |
| Net Margin | -31.9% | -31.9% | -19.4% | 0.6% | 5.7% |
| Balance Sheet | |||||
| Debt/Equity | 2.84 | 2.84 | 1.87 | 1.25 | 0.67 |
| Current Ratio | 0.63 | 0.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $53.2M | $53.2M | $-305.3M | $-460.9M | $-153.6M |
| Returns | |||||
| ROE | -69.6% | -69.6% | -39.2% | 1.1% | 8.5% |
| Valuation | |||||
| P/E | — | — | — | 498.33 | 76.57 |
| EV/EBITDA | — | — | — | 59.21 | 40.69 |
| P/B | 6.49 | 6.49 | 9.94 | 5.28 | 6.47 |
| Growth & Yield | |||||
| Revenue Growth | -36.3% | -36.3% | -21.3% | 18.5% | — |
| EPS Growth | -4.3% | -4.3% | -2400.0% | -85.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.69 → -0.72
Residual
-33.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.